Member Info for GlenFidrich

Forgot to say, thanks also to PCS, Andy, Krone, et al. for taking the time out today to perhaps crystallize a plan of action, should things deteriorate further. Hopefully, news will be forthcoming soon re: 1801/SRA 737/financing from our esteemed BoD.

With the US Federal Reserve signaling a probable reduction in interest rates over the coming months, and therefore an easing in the credit markets, I'm hopeful that things might soon be easier for Sareum with respect to raising funds. Any thoughts?

Feels that way, Warty. I have visions of Tim running around in circles with fingers in both ears, uttering incoherent noises as the clamor for action grows all around him. I really couldn't have mismanaged this better myself - and I would've done it for free!

No one in their right mind would be selling now, except RiverFort. The BoD need to wake up and address the whole financing issue. Their silence on this matter, and their lack of urgency, I'm finding completely unacceptable and disrespectful. What in heaven's name are they playing at? Get a grip!

Not convinced Sareum will still be around to convene an AGM (usually in December). An EGM is what we need.

"Topline results" are not due until Q2 2024, according to last Tuesday's RNS. So, we could be looking at June at the latest. I just hope some positive news re: financing is released sooner than that, otherwise God help the sp.

FunnyGuy, from the latest RNS: "The Board of Directors remains confident that the Company is on course to deliver topline Phase 1a results in Q2 2024". Your contention that "results soon will show a very disappointing outcome" is, at best, mischievous, at worst, downright misleading. If the BoD remains confident, I think I'll take their word on that. Financing, of course, remains a concern, granted.

...consolidation was announced, to the involvement of Peel Hunt, to the financing deal with Riverfort, to the crazy spreads, to the 2.5p incremental falls in the sp (even today) - I should have paid attention to my gut feeling. Never again. An expensive lesson. Someone mentioned Deepmatter. Exactly my thoughts today. We must fight this tooth and nail now.

From yesterday's RNS: "The Company is in discussions to assess alternative funding arrangements". If they are "assessing" alternative funding arrangements, does that mean there are offers already on the table, and these offers are being discussed? It's all a bit shambolic to be honest. All I keep thinking is that in March 2020 the sp stood at 0.25p (12.5p new money). We are still higher today (just), although I know this is scant consolation for most. I just think Sareum is so much further ahead today than it was in 2020, yet the sp is languishing at near the March 2020 levels. Anyone buying in today is surely getting the bargain of a lifetime, or am I completely barking?

Before we start ousting board members, who on earth advised them to go the RF route? If it was PH, their association with SAR has been an unmitigated disaster, so my preference would be to sack them first (or whoever brokered the RF deal). I do feel the pain of many here, but we do know the data have been sound so far, and the volumes have been relatively thin (or at least not enough to warrant the ridiculous drops). My bugbear has been the advertised spreads between the bid and the ask, which is surely deterring new buyers. Why do we drop in 2.5p/5p increments? It would appear excessive given the volumes traded, unless of course someone doesn't want you to buy?

SOG, the wording of the recent RNS ("the CRT Pioneer Fund has entered into a development and commercialization license agreement for SRA737 with a PRIVATE biopharma company based in the United States") would seem to rule out MEI Pharma surely? But what about Allorion Therapeutics? It fits the profile...

https://alloriontx.com

https://www.prnewswire.com/news-releases/allorion-therapeutics-a-next-generation-precision-medicine-company-focusing-on-oncology-and-autoimmune-diseases-raises-50-million-series-b-financing-301767570.html

A quick question. Are the directors allowed to buy if there is a NDA in place? It might explain the radio silence on their part. And for those despairing, a personal anecdote. I was, in March 2020, 70% down on my holding here. I then went to 1000% up (by July 2021), and am now 30% down! Things can change here, and quite rapidly. But having an exit strategy is always a good idea. Trust me!

Top of the share risers board yesterday (for a while, at least), and now top of the share fallers today, on volume of around 150,000 shares (or roughly 0.2% of shares in issue). Go figure...

The whole "subject to financing" concern is real, but should not be overstated. I remember reading something similar many times in previous RNSs. So I decided to check, and the first one I checked (from August 2021), I found this: "The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing." I'm quite sure there are other examples from even before 2021. The RF deal is, admittedly, a shocker but somehow Sareum continues to stay afloat. And not only that, it continues to impress in clinical trials, as per yesterday's RNS. Patience, as ever, is the key here.

Sorry, Darien, forgive me, but were you calling 0.8p back in March 2022? All I can find in your post history is you saying in December 2020 that the Sar sp would be back to 1p "in a month". It actually went on to reach 9p by August 2021! Also, in the last 30 days, you have posted only once on the Sar bb - today - presumably just to stick the boot in? You seem to be familiar with snake oil salesmen, though...

Just wondering why the BoD are not buying at these bargain basement prices? I mean, Sareum is in a much better position now than when the SP last saw these lows (0.8p in old money).

But isn't it the science that will determine Sareum's future? You either believe in it, or not. I think it should be "trust the scientists" and Tim and John (I believe) are leaders in their field. The current SP equates to roughly 0.9p in old money - my original average. It then 10 bagged from there. The real question is, can lightning strike twice?

High-end watch prices (for Rolex, PP, AP, for example) seem to be stabilizing, so there's some hope WOSG has seen the worst. Rolex acquiring Bucherer might pose a more systemic risk to WOSG, however. Not really sure. One thing I'm hearing is some new watches are now appearing 'under list' on the grey market, and some less desirable brands are even being offered at a discount to their retail price at ADs (including Omega, Breitling, etc.).

So, yesterday's drop was to accommodate PH's mates then? Seen it all before. Hope no one was spooked into selling...

Its likely promotion to the FTSE 250 should attract the interest of portfolio managers. As I said before, this rise has legs. Hold.